Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2016

01-12-2016 | Original Research

Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer

Authors: Alavieh Fateh, Mohammad Ali Hosseinpour Feizi, Reza Safaralizadeh, Shirin Azarbarzin, Reyhaneh Ravanbakhsh

Published in: Journal of Gastrointestinal Cancer | Issue 4/2016

Login to get access

Abstract

Introduction

MicroRNAs are non-coding RNAs that regulate the gene expression at post-transcriptional level. This futuristic study characterized the contribution of miR-1287 to the colorectal cancer (CRC) tumorigenesis.

Methods

The real-time reverse transcription–polymerase chain reaction was used to examine miR-1287 expression levels, prospectively in 40 pairs of CRC tissue samples and adjacent noncancerous tissues (>2 cm from cancer tissue).

Results

No significant relationship was found between miR-1287 expression levels and clinicopathological features. Showing significant changes overall, MiR-1287 was significantly upregulated in the group of CRC samples compared with matched noncancerous tissue samples. A receiver operating characteristic (ROC) curve also showed ROC area (AROC) of 34 % with 1.0 and 0.02 sensitivity and specificity, respectively. Expression of miR-1287, with a value of 0.34, P value = 1.98, and P > 0.05, revealed that this microRNA has a low sensitivity and specificity to be regarded as a tumor marker.

Conclusions

With regard to recent increased rate of CRC in the world, the present study may be a contribution, though very small, in the diagnosis and consequently in the treatment of CRC patients.
Literature
1.
go back to reference Chalya PL et al. Clinicopathological patterns and challenges of management of colorectal cancer in a resource-limited setting: a Tanzanian experience. World J Surg Oncol. 2013;11(1):88–97.CrossRefPubMedPubMedCentral Chalya PL et al. Clinicopathological patterns and challenges of management of colorectal cancer in a resource-limited setting: a Tanzanian experience. World J Surg Oncol. 2013;11(1):88–97.CrossRefPubMedPubMedCentral
2.
3.
4.
go back to reference Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis. 2008;23(7):683–8.CrossRefPubMed Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis. 2008;23(7):683–8.CrossRefPubMed
5.
go back to reference Somi MH et al. Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev. 2014;15(9):3945–9.CrossRefPubMed Somi MH et al. Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev. 2014;15(9):3945–9.CrossRefPubMed
6.
go back to reference Ferlay J et al. GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013. globocan. iarc. fr, 2015. Ferlay J et al. GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013. globocan. iarc. fr, 2015.
8.
go back to reference Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;11(2):281–97.CrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;11(2):281–97.CrossRef
9.
go back to reference Bentwich I et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37(7):766–70.CrossRefPubMed Bentwich I et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37(7):766–70.CrossRefPubMed
12.
go back to reference Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol. 2008;26(17):2828–38.CrossRefPubMed Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol. 2008;26(17):2828–38.CrossRefPubMed
13.
go back to reference Hogan NM, Joyce MR, Kerin MJ. MicroRNA expression in colorectal cancer. Cancer Biomark. 2012;11(6):239–43.PubMed Hogan NM, Joyce MR, Kerin MJ. MicroRNA expression in colorectal cancer. Cancer Biomark. 2012;11(6):239–43.PubMed
14.
go back to reference Cai C et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One. 2012;7(1):e29750.CrossRefPubMedPubMedCentral Cai C et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One. 2012;7(1):e29750.CrossRefPubMedPubMedCentral
15.
16.
go back to reference Wang Y et al. Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data. Cancer Genet. 2013;206(9-10):340–6.CrossRefPubMed Wang Y et al. Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data. Cancer Genet. 2013;206(9-10):340–6.CrossRefPubMed
17.
go back to reference Wu G et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7(4):1449.PubMedPubMedCentral Wu G et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7(4):1449.PubMedPubMedCentral
18.
go back to reference Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer journal (Sudbury, Mass). 2012;18(3):244.CrossRef Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer journal (Sudbury, Mass). 2012;18(3):244.CrossRef
19.
go back to reference Xi Y et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2006;2:113–21.PubMed Xi Y et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights. 2006;2:113–21.PubMed
20.
21.
go back to reference Wang W et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica. 2012;97(4):586–94.CrossRefPubMedPubMedCentral Wang W et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica. 2012;97(4):586–94.CrossRefPubMedPubMedCentral
22.
go back to reference Guo L et al. Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer. Mol Biol Rep. 2013;40(3):2175–86.CrossRefPubMed Guo L et al. Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer. Mol Biol Rep. 2013;40(3):2175–86.CrossRefPubMed
23.
go back to reference Shen J et al. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. Carcinogenesis. 2012;33(3):604–12.CrossRefPubMedPubMedCentral Shen J et al. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. Carcinogenesis. 2012;33(3):604–12.CrossRefPubMedPubMedCentral
Metadata
Title
Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer
Authors
Alavieh Fateh
Mohammad Ali Hosseinpour Feizi
Reza Safaralizadeh
Shirin Azarbarzin
Reyhaneh Ravanbakhsh
Publication date
01-12-2016
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2016
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9833-5

Other articles of this Issue 4/2016

Journal of Gastrointestinal Cancer 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.